# IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Source: https://onco.cc/trials/nct05155254/  
OnCo record `nct05155254` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing IO102-IO103 in melanoma, active and no longer recruiting.

## Summary

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) is a phase 3 interventional study registered as NCT05155254, led by IO Biotech with Syneos Health and Merck Sharp & Dohme, and active but no longer recruiting on the registry. Official title: An Open-label, Randomised, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18). Planned enrolment is 407 participants (actual). The study started in 2022-05-17 and primary completion is expected in 2025-05-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05155254
- Phase: 3
- Setting: An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)
- Sponsor: IO Biotech
- Enrolled: 407

## Sources

- ClinicalTrials.gov NCT05155254: https://clinicaltrials.gov/study/NCT05155254

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [IO102-IO103](https://onco.cc/drugs/io102-io103/)
- companies: [IO Biotech](https://onco.cc/companies/io-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05155254.json